Brief: Inozyme Pharma Announces Authorization To Proceed In U.S. And U.K. With Phase 1/2 Clinical Trial Of Inz-701 For The Treatment Of Enpp1 Deficiency

Inozyme Pharma

04/01/2021 12:07

Jan 4 (Reuters) - Inozyme Pharma Inc  INZY.O :
    * INOZYME PHARMA ANNOUNCES AUTHORIZATION TO PROCEED IN U.S.
AND
U.K. WITH PHASE 1/2 CLINICAL TRIAL OF INZ-701 FOR THE TREATMENT
OF ENPP1 DEFICIENCY
    * INOZYME PHARMA INC - EXPECTS TO ENROLL FIRST SUBJECT IN
FIRST
HALF OF 2021 AND PROVIDE PRELIMINARY SAFETY AND BIOMARKER DATA
IN SECOND HALF OF 2021

Source text for Eikon:  ID:nGNX8KrtbK 
Further company coverage:  INZY.O 

 ((Reuters.Briefs@thomsonreuters.com;))